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Thioglycosides offer the advantage over O-glycosides to be resistant to hydrolysis. Based on initial
evidence of this recognition ability for glycosyldisulfides by screening dynamic combinatorial libraries,
we have now systematically studied dithiodigalactoside on a plant toxin (Viscum album agglutinin) and
five human lectins (adhesion/growth-regulatory galectins with medical relevance e.g. in tumor
progression and spread). Inhibition assays with surface-presented neoglycoprotein and in solution
monitored by saturation transfer difference NMR spectroscopy, flanked by epitope mapping, as well as
isothermal titration calorimetry revealed binding properties to VAA (Ka: 1560 ± 20 M-1). They were
reflected by the structural model and the affinity on the level of toxin-exposed cells. In comparison,
galectins were considerably less reactive, with intrafamily grading down to very minor reactivity for
tandem-repeat-type galectins, as quantitated by radioassays for both domains of galectin-4. Model
building indicated contact formation to be restricted to only one galactose moiety, in contrast to
thiodigalactoside. The tested glycosyldisulfide exhibits selectivity between the plant toxin and the tested
human lectins, and also between these proteins. Therefore, glycosyldisulfides have potential as chemical
platform for inhibitor design.
Introduction
The growing insights into the molecular basis of physiological
processes guide the selection of new targets for drug design.
Owing to the unsurpassed capacity of glycans to store biological
information, the development of a wide array of respective
receptors (lectins) and their dynamic interplay triggering specific
cellular responses e.g. in growth regulation, the design of com-
pounds that potently interfere with lectin-glycan recognition has
become a challenge.1 Initially mostly addressed for plant lectins
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such as concanavalin A, the selection is shifting to medically
relevant proteins, that is, to distinct biohazardous toxins and
human lectins. Technically, the aim of identifying promising
anti-lectin lead compounds prompted the introduction of high-
throughput screening and diverse types of library approaches.2
Along these lines, we have targeted on two such classes of
galactoside-binding lectins (toxic AB-type lectins, here Viscum
album agglutinin (VAA), and the family of adhesion/growth-
regulatory galectins with its three groups of proto-, chimera-
and tandem-repeat-type proteins3) and applied the dynamic
combinatorial library approach based on thiol-disulfide exchange
with thioglycosides.4 As previously demonstrated, the dynamic
library approach is indeed a viable route to identifying new
disulfide ligands for lectins.4d Nevertheless, the main objective of
this study has not been to further explore this methodology, but
rather to evaluate the properties of a ligand that was previously
identified.
In principle, S-glycosides have the pharmacodynamic advantage
of being resistant to hydrolytic cleavage. However, the substitution
engenders enhancement of flexibility and alteration of the topol-
ogy (C–S/C–O bond lengths: 1.78 A˚ vs. 1.41 A˚; C–S–C/C–O–C
bond angles: 98◦ vs. 117◦).5 These differences from O-glycosides
put bioactivity of these derivatives into question. However, by
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testing thiodigalactoside (TDG) in inhibition assays, the S-
glycosidic bond has been shown to interact with AB-type plant
toxins and galectins, with a tendency for an increased entropic
penalty compensated by an enthalpic gain relative to lactose in the
thermodynamic balance sheet.6 Moving beyond thioglycosides,
the synthesis of glycosyldisulfides had been motivated to make
effective glycosyl donors and a new class of test compounds
available.7 In this respect, our screening of disulfide-forming
thioglycoside libraries with the toxin from mistletoe had indeed
indicated a potential of dithiodigalactoside (DTDG) to protect
a human cell line from toxin binding.4d Also, the asymmet-
ric disulfide of N-acetylated galactosamine and glucosamine,
a derivative of di-N-acetylated lactose, appeared to harbour
reactivity for galectin-3.4d These initial results on bioactivity of
a diglycosyldisulfide prompted us to systematically investigate the
reactivity profile of DTDG relative to TDG and lactose. In detail,
we addressed the following issues:
a.) to determine its binding capacity to the mistletoe toxin in
two assay systems of increasing biorelevance,
b.) to provide a structural model for binding, and
c.) to determine the relative reactivity to human galectins from
each of the three groups listed above, to build a structural model
for a representative complex and to run assays with the two
separate domains of a tandem-repeat-type family member, i.e.
galectin-4.
Technically, ligand properties of the synthetic product were
assessed by spectrophotometric and radioactivity-based inhibition
assays, epitope mapping and competitive binding analysis in sat-
uration transfer difference (STD) NMR spectroscopy, isothermal
titration calorimetry (ITC) and fluorescent cell assays, flanked by
computational docking to visualize a model for the formation of
lectin-glycosyldisulfide complexes.
Results and discussion
Synthesis
The symmetrical disulfide was obtained in a three-step procedure
using a solution of iodine in ethanol in the last step, as outlined in
Scheme 1. This compound was used to probe for its ligand proper-
ties on the plant toxin in biochemical, ITC, NMR spectroscopical
and cell biological assays.
Assaying ligand properties on the toxin
A convenient test method is the analysis of the extent of
lectin binding to surface-presented glycans in the absence and
presence of compounds examined for inhibitory activity. Using
lactose as interaction partner by adsorbing a lactose-bearing
neoglycoprotein to the surface of microtiter plate wells, binding of
biotinylated VAAwas first ascertained to be saturable and blocked
by presence of cognate sugar but not mannose or glucose. The
dependence on binding the carbohydrate specifically was further
substantiated by lack of VAA interaction with a neoglycoprotein
constituted by the same carrier protein (bovine serumalbumin) but
presenting mannose as sugar headgroup. Next, conditions were
defined to ensure signal intensity in the linear range by varying
the lectin concentration in order to reach optimal sensitivity.
The ensuing inhibitory titrations at constant lectin concentration
with increasing concentrations of tested compounds resulted in
a reduction of the extent of binding of the labelled toxin to the
ligand-bearing matrix (Fig. 1). TDG was a slightly more efficient
inhibitor than lactose when expressed in the measured IC50-values
(Table 1). Thus, the solid-phase inhibition assay was suitable to
determine reactivity and to provide a comparativemeasure. Tested
under these conditions, DTDG obviously had inhibitory capacity
(Fig. 1). It was about 2–3-fold lower than for TDG (Table 1).
Fig. 1 Titration curves illustrating the course of inhibition of binding
of biotinylated VAA (3 mg ml-1) to lactosylated neoglycoprotein in a
solid-phase assay by increasing concentrations of thiodigalactoside (),
dithiodigalactoside () and lactose ().
Scheme 1 Reagents and conditions: a) HSAc, BF3·Et2O, CH2Cl2, 0 ◦C - rt, 24 h (89%); b) NaOMe, MeOH, 2 h (97%); c) H2O, I2-EtOH.
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Table 1 Relative inhibitory potency of lactose (Lac), thiodigalactoside
(TDG) and dithiodigalactoside (DTDG) on lectin binding to a surface-
immoblized neoglycoprotein (expressed as IC50-value, in mM)a
Lectin Lac TDG DTDG
VAA (3 mg ml-1) 0.6 0.4 1.1
galectin-1 (20 mg ml-1) 0.8 0.5 4.8
galectin-3 (15 mg ml-1) 1.6 1.1 5.4
galectin-4 (5 mg ml-1) 3.5 1.8 > 10
galectin-7 (30 mg ml-1) 4.0 2.3 > 10
galectin-8 (0.1 mg ml-1) 1.2 1.4 > 10
a Titrations were performed using a constant coating concentration of
neoglycoprotein (0.25 mg/well) with eight concentrations of sugar in
triplicates and up to six independent series, reaching an upper limit of
13.7% for the standard deviation (for exemplary titration curve, please see
Fig. 1).
These results intimated a direct competition between the natural
b-galactoside presented by the neoglycoprotein and the tested
thiocompounds. To independently verify this assumption we next
ran direct competition assays in solution, monitored by STD
NMR spectroscopy.
In this setting, lactose was the reporter ligand, whose contact
profile, which underlies magnetization transfer from the saturated
protein to distinct ligand protons, is known.8 A reduction of
the intensity of these signals of lactose in the presence of
an inhibitor reflects the loss of lectin-lactose contact and the
relative inhibitory capacity of the tested compound. The respective
titrations confirmed the inhibitory activity ofDTDGand yielded a
relative potency of about 0.5–0.7fold for DTDG when compared
to TDG. Since these experiments further documented complex
formation with the disulfide, we proceeded to perform isothermal
titration calorimetry for direct affinity measurement, using TDG
as positive control.
Representative ITC curves for both compounds are shown
in Fig. 2A. Titration data obtained with both DTDG and
TDG could be fitted to a one-set-of-sites model with association
constants, Ka, of 1560 ± 20 M-1 (DG = -18.16 ± 0.03 kJ mol-1)
and 2600 ± 100 M-1 (DG = -19.4 ± 0.1 kJ mol-1), respectively.
A reliable determination of the binding stoichiometry for this
range of affinities would require running the titrations at protein
concentrations over the natural solubility level of VAA. Therefore,
only total estimates of enthalpy/entropy changes per B chain,
-50.3 ± 0.4 kJ mol-1/-108 ± 1 J mol-1 K-1 (DTDG) and -53 ±
1 kJ mol-1/-110 ± 30 J mol-1 K-1 (TDG), were derived from the
analysis. ITC data obtained for lactose under similar conditions9
were consistent with two sets of sites with Ka of 1.1 ¥ 103 M-1
and 1.6 ¥ 104 M-1, assigned to 2g (Tyr-sites) and 1a (Trp-sites)
subdomains of the B-chains, respectively, the accessibility to the
Trp-sites being restricted by tetramer formation. The fact that
data obtained for DTDG and TDG could be fitted to a one-set-
of-sites model imply that if both Tyr- and Trp-sites are operative
for binding the thioderivatives, they must exhibit similar affinities.
At any rate, DTDG binds to VAA with lower affinity than TDG.
Having herewith determined the affinity of DTDG to the
toxin, STD NMR spectroscopy was used for epitope mapping
by recording proton signals of the ligand when separately running
experiments with lactose, TDG and DTDG. The primary contact
of disaccharides with VAA is the galactose unit, and the penulti-
Fig. 2 Calorimetric titration of VAA (A) and human galectin-4 (B) with
thiodigalactoside () and dithiodigalactoside (). Representative plots of
the heat released per mole of ligand injected in the course of titrations as a
function of the sugar/protein molar ratio. Solutions of VAA at 337.5 mM
()/243 mM () (in terms of AB heterodimer concentration) and of
galectin-4 at 117 mM ()/154.7 mM () were used in these titrations.
Solid lines correspond to the best fit of the experimental data using a
one-set-of-sites model.
mate sugar moiety of disaccharides is known to lose its mobility
to varying degrees.10 As exemplarily shown by the strong signals
in the case of DTDG (Fig. 3 left), ligand protons at positions 2, 3
and 4 in the galactose pyranose ring appear to be in close vicinity
to the protein in all three sugars, irrespective of the nature of the
glycosidic bond. This experimental observation agrees with the
conclusions derived from chemical-mapping studies,6i and can be
readily reconciled with the model of the complex obtained by in
silico docking (Fig. 4). The predicted binding patterns for TDG
andDTDGwere nearly indistinguishable.Main interactions at the
Tyr-sites for both thiocompounds are hydrogen bonds involving
hydroxyl groups at positionsO3 (withAsp235 andAsn256) andO4
(with Gln238) as well as CH-p interactions of pyranose hydrogens
H3, H4 and H5 with Tyr249. The second galactose unit can
Fig. 3 Illustration of relative STD signal intensities of protons for the
galactosemoiety of dithiodigalactoside binding to theTyr site ofVAA(left)
and to human galectin-1 (right). The 500 MHz off-resonance (above) and
the STD (below) spectra are presented in the lower panel. The STD signals
(even amplified 128 fold) for the hgal-1 complex are very weak indicating
that the binding affinity is very low. This feature strongly contrasts with the
observation for the VAA complex (amplified 8 fold). The asterisk denotes
the presence of a small amount of ethanol in the sample, which does not
give STD signal.
This journal is © The Royal Society of Chemistry 2011 Org. Biomol. Chem., 2011, 9, 5445–5455 | 5447
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Fig. 4 Structural model of the complex of VAA (Tyr site, surface rep-
resentation) with thiodigalactoside (green) and dithiodigalactoside (grey),
based on docking analysis and the experimental input from STD NMR
spectroscopy. While one galactose unit makes several contacts (hydrogen
bonds with Asp235 and Asn256, and CH-p interactions with Tyr249 (with
its van der Waals surface emphasized by the dots representation)), the
second moiety contributes weakly to complex stabilization with Gln238 in
the case of TDG. The van der Waals surfaces are emphasized with the grid
and the dots.
contact Glu238 as part of TDG but not of DTDG (Fig. 4). After
having herewith characterized the ligand properties of DTDG
and presented a structural model of the complex, it was an open
question whether the disulfide can protect human cells from toxin
binding, hereby increasing the biorelevance of testing.
In analogy to the solid-phase test system, concentration de-
pendence and inhibition were first ascertained for VAA binding
to cells, here B-lymphoblastic Croco II cells (Fig. 5A, B). The
comparative study of the inhibitory potency of galactose and
lactose (Fig. 5C) and TDG/DTDG (Fig. 5D) under identical
conditions revealed a graded potency, starting with TDG as
frontrunner, and underlined the activity of DTDG. Since the
glycomic profile and spatial parameters of glycan presentation can
differ among various cell lines, we ran the respective assays with
a line of another histogenetic origin, i.e. colon adenocarcinoma
cells, and obtained a similar grading (Fig. 5E, F). In aggregate,
these results are in accord with the affinity determinations and
prove that DTDG can impair carbohydrate-dependent toxin
binding to two types of human cells. Since this lectin’s b-trefoil
folding is different from the architecture of the b-sandwich-type
carbohydrate recognition domain of galectins, which also have
extended sites for ligand contacts beyond the galactose core, as
inferred by binding assays, NMR spectroscopical monitoring and
molecular modelling,6,11 it is an open question whether DTDG
is a galectin ligand. Moreover, intrafamily sequence divergence
around the carbohydrate recognition site in galectin genes may
lead to differential reactivity. Thus, we tested galectins from each
of the three structural subgroups (proto-type with galectins-1
and -7, chimera-type with galectin-3 and tandem-repeat-type with
galectins-4 and -8) to address this additional issue.
Assaying ligand properties on human galectins
The conditions of the solid-phase assay were first optimized for
each galectin. The obtained results with TDG were in line with
Fig. 5 Semilogarithmic representation of fluorescent surface staining
subsequent to VAA binding of cells of the human B-lymphoblastoid
line Croco II (A–D; 0.5 mg ml-1 VAA in B–D) and of the human colon
adenocarcinoma line SW480 (E, F: 2 mg ml-1 VAA). The control value of
cell positivity by the second-step reagent in the absence of lectin is given
as grey-shaded area, the 100%-value (lectin staining in the absence of
inhibitor) as thick black line. Numbers characterizing staining (percentage
of positive cells/meanfluorescence intensity) in each panel are always given
in the order of listing (from top to bottom). A: dependence of staining from
increasing the concentration of VAA from 0.2 mg ml-1 to 0.5 mg ml-1, 2 mg
ml-1 and 4 mg ml-1. B: inhibition of VAA-dependent staining by increasing
the concentration of lactose from 1 mM to 2 mM, 5 mM and 10 mM
(numbers correspond to control value, presence of 10 mM lactose and the
100%-value). C, D: staining parameters in the presence of 5 mM inhibitor
(C: lactose, galactose; D: TDG, DTDG). E, F: staining parameters of the
colon cancer cells in the presence of 5 mM inhibitor (E: lactose, DTDG;
F: TDG, galactose).
the known reactivity of galectins-1, -3 and -76 and extended the
reactivity profile to the tandem-repeat-type galectins-4 and -8
(Table 1). When introducing DTDG to the assays, non-uniform
5448 | Org. Biomol. Chem., 2011, 9, 5445–5455 This journal is © The Royal Society of Chemistry 2011
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responses at comparatively high concentrations were registered
(Table 1). Galectins-1 and -3 were sensitive to DTDG presence,
albeit weakly in relation to the plant toxin, whereas the other
galectins reacted poorly with the disulfide (Table 1). The use of
tumor cell extracts as source for glycoproteins instead of the
neoglycoprotein did not alter this result, excluding any ligand-
type-related bias. For example, galectin-3 binding was reduced by
the three tested compounds with IC50-values of 0.8 mM (TDG),
1.2 mM (lactose) and 4.4 mM (DTDG), as similarly seen with the
neoglycoprotein (Table 1).
These results were corroborated by STD NMR spectroscopical
series, which revealed a rather weak or no activity for DTDG
for the galectins. Guiding model building to explain the negative
impact of the disulfide linkage on galectin binding, the STD-
based epitope mapping for TDG showed intense signals for the
H4, H5 and H6 protons, the characteristic signature for galectin
contact (Fig. 3 right). These data, together with the crystal
structures of the galectin of toad ovary and human galectin-1
in complex with TDG,12 provided the input and quality control
for molecular modeling studies. Similar to lactose, TDG thus
engages both moieties of the disaccharide for binding to galectin-
1. This pattern changes due to the presence of the disulfide in
the glycosidic linkage. One sugar residue still enters the binding
site and maintains the contact pattern, whereas the second would
be completely exposed to the solvent, with arrest of the angle of
the S–S bond at about 90◦ (Fig. 6A). The structural constellation
remained rather stable over the entire 6-ns period of the MD
simulation. Of note, the analysis of the MD trajectories, after
superimposition of the two galectin-1/ligand complexes, enabled
identification of awatermolecule, which could take the place of the
OH2 group of TDG in mediating the hydrogen-bonding network
with Arg48/Glu71 shown in Fig. 6B. Overall, the disclosed lack of
contact building beyond the interacting galactose of the symmetric
diglycosyldisulfide will then, apparently, set strict limits to the
affinity. Evidently, the disulfide bonding, itself being subject to a
conformational arrest, impairs the potential for interacting with
galectins.
This impairment was also seen on the level of cell binding, where
galectins interactwith complex glycans of natural glycoconjugates,
as documented by cytofluorimetric analysis with galectin-3 and
colon adenocarcinoma cells (Fig. 7A, B) as well as for galectin-4
and pancreatic adenocarcinoma cells (Fig. 7C–F). In the latter
case, the apparent strongly negative impact on inhibitory potency
was further confirmed by ITC (Fig. 2B). Addition of DTDG
to the galectin-4-containing solution triggered only negligible
heat generation, comparable to the signal of ligand dilution
(Fig. 2B). The titration profiles also highlight the conspicuous
reactivity difference to the toxin shown in panel A. Titrations
with TDG and galectin-4 as positive control yieled an association
constant of 1210 ± 30 M-1 (DG = -17.53 ± 0.07 kJ mol-1) and
estimated enthalpy/entropy values of -39.9 ± 0.8 kJ mol-1/-75 ±
3 J mol-1 K-1 based on a one-set-of-sites model (assuming two
equivalent and independent sites per molecule), and no evidence
for cooperativity. Lactose binds similarly with a comparatively
lower affinity (Ka = 585 ± 8 M-1; DG = -15.74 ± 0.03 kJ mol-1) due
to an increased entropic penalty (DH = -43 ± 2 kJ mol-1, DS =
-93 ± 7 J mol-1 K-1) (not shown).
Finally, to track down ligand properties of DTDG at a very
sensitive level, we performed radiobinding assays to lactose-
Fig. 6 Illustrationof themodels of the average structures of the complexes
of human galectin-1 with dithiodigalactoside (A) based on MD simu-
lations showing the key intermolecular contacts. Different perspectives
in the full and expanded views are offered for the sake of clarity. (B)
Superimposition of the complexes with TDG (thiodiglycoside in white)
andDTDG (diglycosyldisulfide inmagenta), also revealing the presence of
the water molecule that, in the second complex, substitutes the OH2 of the
second galactose moiety of TDG to mediate a hydrogen-bonding network
with Arg48 and Glu71. Intermolecular hydrogen bonds are highlighted
with lines.
presenting agarose beads and a surface-presented glycoprotein
(asialofibrin films) with iodinated protein using the two galectin-4
domains separately. These experiments will also inform us about
the binding properties of the two, structurally distinct domains
of galectin-4. Extent of binding of the labelled lectin domains
was measured in presence of increasing concentrations of lactose,
TDGandDTDG.Apparent association constants were calculated
from the plot of the reciprocal of the lectin fraction bound to the
ligand vs. the inhibitor concentration.13 A representative plot of
data for the C-terminal domain is given in Fig. 8. In relation to
the ITC data for the full-length form of galectin-4, the association
This journal is © The Royal Society of Chemistry 2011 Org. Biomol. Chem., 2011, 9, 5445–5455 | 5449
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Fig. 7 Semilogarithmic representation of fluorescent surface staining upon binding of galectin-3 (A, B) and galectin-4 (C–F) of cells of the human colon
adenocarcinoma line SW480 (A, B) and the pancreatic adenocarcinoma line Capan-1 with functional tumor suppressor p16INK4a (C–F). For details on
presentation, please see legend to Fig. 5. A, B: staining parameters in the presence of 2 mM inhibitor for galectin-3 at 10 mg ml-1 (A: lactose, galactose;
B: TDG, DTDG). C, D: staining parameters in the presence of 2 mM inhibitors for galectin-4 at 20 mg ml-1 (C: lactose, galactose; D: TDG, DTDG). E,
F: staining parameters in the presence of 20 mM DTDG (E) and in the presence of decreasing concentrations of TDG (F: 20 mM, 10 mM, 5 mM).
constants for lactose were in the same range with values of 300 ±
40 M-1 and 440 ± 60 M-1 for the N- and C-terminal domains,
respectively. Thus, the fit for the one-set-of-sites model of ITC
data is attributable to this similarity. The affinity increase for
TDG was also determined, with Ka-values of 730 ± 90 M-1 and
670 ± 50 M-1, respectively. This set-up enabled to trace even minor
DTDG reactivity. By going up to 10 mM DTDG, lectin binding
to the matrix-presented ligand was reduced by about 25%, from
which an upper limit of the association constant at <30 M-1
could be estimated for both domains. Thus, DTDG is definitely
only a very weak ligand for galectin-4, on the level of both
domains.
5450 | Org. Biomol. Chem., 2011, 9, 5445–5455 This journal is © The Royal Society of Chemistry 2011
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Fig. 8 Inhibitory potency of lactose (), thiodigalactoside () and
dithiodigalactoside () on the binding of the C-terminal domain of
galectin-4 in a solid-phase radioassay. The extent of binding of the
125I-labelled domain to asialofibrin films (100 mg) presented on the plastic
microwell surface was measured in the absence and presence of different
concentrations of the tested sugar compounds.
Conclusions
Work with dynamic combinatorial thioglycoside libraries had
indicated potential for DTDG to react with an AB-type plant
toxin.4d The results reported here define DTDG as ligand in
different biochemical assays, characterize its respective properties
in structural terms and document its capacity to protect human
cells from toxin binding. The same panel of strategically combined
experimental and computational methods delineated a significant
difference in reactivity to human galectins, notably with intrafam-
ily grading. Glycosyldisulfides are thus a new substance platform
to accomplish selective inhibition of this class of endogenous
lectins and a plant AB-type toxin. The computation of a structural
model revealed a lack of contact of the second galactose moiety in
the case of the disulfide. Exploration of additional substitutions
at the 2¢- and 3¢-positions, e.g. 2¢-fucosylation,14 the introduction
of anomeric and aglyconic extensions2g,8,15 and the conjugation
to certain scaffolds, e.g. starburst glycodendrimers, cyclodextrin,
glycocyclophanes or cyclic neoglycopeptides,16 are routes to
further increase the level of affinity and selectivity. This also
applies to capitalize on intrafamily differences among galectins,
when aiming to block a certain protein in a functional context
such as tumor progression or intergalectin competition during
growth regulation.17 Having herewith revealed the bioactivity of
the symmetric dithiodigalactoside, it is an emerging question
whether the respective selenides, whose conformational flexibility
can resemble that of thioglycosides,18 will be lectin ligands.
Experimental
Materials and general methods
All commercial reagents and solvents were used as received.
Chemical reactions were monitored with thin-layer chromatog-
raphy using precoated silica gel 60 (0.25 mm thickness) plates.
Flash column chromatography was performed on silica gel 60
(0.040–0.063mm). 1H-NMRand 13C-NMR spectra were recorded
on a Bruker Avance 400 spectrometer at 400 (100) MHz and/or
Bruker Avance DMX 500 at 500 (125) MHz, respectively. Com-
pound 1 was purchased from Sigma.
2,3,4,6-Tetra-O-acetyl-1-S-acetyl-1-thio-b-D-galactopyranose
(adapted from 4b,19a) (2)19b
1,2,3,4,6-Penta-O-acetyl-b-D-galactopyranose (1) (2 g,
5.13 mmol; please see Scheme 1) and thioacetic acid (1.52
ml, 21.51 mmol) were dissolved in dry CH2Cl2 (25 ml) at 0 ◦C,
and BF3·Et2O (3.889 ml, 31.51 mmol) was added dropwise over
a period of 15 min. The reaction mixture was allowed to warm
to ambient temperature and stirred under nitrogen protection
for 24 h. The reaction mixture was then poured onto ice-cold
water, and extracted with CH2Cl2. The combined organic layers
were successively washed with NaHCO3, water and brine, dried
over MgSO4, and filtered. The crude product was purified by
column chromatography (eluent: hexane/EtOAc 3 : 1) to give
2,3,4,6-tetra-O-acetyl-1-S-acetyl-1-thio-b-D-galactopyranose
(2)19b (1.85 g, 4.56 mmol, yield 89%). mp 117 ◦C. 1H NMR
(CDCl3, 500 MHz): d (ppm) 5.45 (d, 1H, J = 3.4 Hz, H-4), 5.32
(t, 1H, J = 10.1 Hz, H-2), 5.25 (d, 1H, J = 10.2 Hz, H-1), 5.11 (dd,
1H, J = 3.4, 9.8 Hz, H-3), 4.03–4.16 (m, 3H, H-5, H-6, H-6¢), 2.39
(s, 3H, SCOCH3), 2.08, 2.03, 2.02, 2.01 (12H, 4 s, 4 OCOCH3);
13C NMR (CDCl3, 125 MHz): d (ppm) 192.1, 170.3, 170.1, 169.9,
19.5, 80.6, 75.0, 71.9, 67.2, 66.3, 61.2, 30.8, 20.7, 20.6, 20.6, 20.5.
MS (ESI): m/z = 429.06 [M + Na+], C16H22O10S; found 429.00.
1-Thio-b-D-galactopyranose sodium salt (3)19b
Compound 2 (1.85 g, 4.56 mmol, yield 89%) was dissolved in a
MeOH solution (15 ml) of NaOMe (271 mg, 5.02 mmol). The
chemical reaction in the resulting mixture quantitatively yielded
product 3. 1H-NMR (500 MHz, D2O): d = 4.49 (d, J = 9.1 Hz, 1H,
H-1), 3.92 (d, J = 3.6 Hz, 1H, H-4), 3.74 (dd, J = 11.2, 7.6 Hz, 1H,
H-6), 3.61–3.69 (m, 2H, H-5, H-6¢), 3.58 (dd, J = 9.5, 3.6 Hz, 1H,
H-3), 3.31 (t, J = 9.2 Hz, 1H, H-2). 13C NMR (D2O, 125 MHz): d
(ppm) 85.8, 80.1, 77.4, 75.1, 71.0, 62.7.
1,1¢-Dithio-b-D-digalactopyranoside (4)19c
Compound 3 (0.2 g, 0.92 mmol) was dissolved in water (3 ml),
and a saturated ethanolic solution of iodine was added dropwise
until a persistent yellow color appeared in themixture. The solvent
was evaporated, the crude product was dissolved in MeOH and
precipitated by the addition of an excess of EtOAc. Filtration of
the white solid yielded pure compound 419c in good yield (0.16 g,
0.41 mmol, yield 89%). The procedure was repeated twice to
remove remaining traces of compound 3. 1H NMR (D2O, 500
MHz): d (ppm) 4.54 (d, 2H, J = 9.7 Hz, H-1, H¢-1), 3.97 (d, 2H,
J = 3.26 Hz, H-4, H¢-4), 3.83 (t, 2H, J = 9.7 Hz, H-2, H¢-2), 3.72–
3.80 (m, 4H, H-5, H¢-5, H-6, H¢-6), 3.72 (dd, 2H, J = 3.1, 12.3 Hz,
H-6¢, H¢-6¢), 3.69 (dd, 2H, J = 3.3, 9.5 Hz, H-3, H¢-3); 13C NMR
(D2O, 125 MHz): d (ppm) 89.9, 79.6, 73.9, 68.8, 68.7, 61.1.
Lectin purification and quality controls
Purification of the lectins started from extracts of dried mistletoe
leaves (VAA) and bacterial pellets after recombinant production
This journal is © The Royal Society of Chemistry 2011 Org. Biomol. Chem., 2011, 9, 5445–5455 | 5451
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(human full-length galectins and the two separate galectin-4
domains) and included affinity chromatography on lactosylated
Sepharose 4B, obtained after divinyl sulfone activation, as central
step.20 Purity was routinely ensured by one- and two-dimensional
gel electrophoresis andmass spectrometry, quaternary structure by
gel filtration and activity by i) haemagglutination using trypsin-
treated and glutaraldehyde-fixed rabbit erythrocytes, ii) toxicity
tests on human tumor lines (Croco II, SW480) and iii) anoikis
assays on a responsive cell line (Capan-1).21 Biotinylation of
the lectins with the N-hydroxysuccinimide ester derivative of
biotin (Sigma, Munich, Germany) was performed under activity-
preserving conditions and was followed by mass spectrometric
product analysis to quantify label incorporation and identify sites
of conjugation.22
Inhibition spectrophotometric assay
Neoglycoprotein (bovine serum albumin free of contaminating
glycoproteins after conjugation of the p-isothiocyanatophenyl
derivative of lactose23) was adsorbed to the surface of microtiter
plate wells (0.25 mg/well in 50 ml) from phosphate-buffered saline
at 4 ◦C overnight, and residual sites on the plastic surface for
binding proteins were then saturated for 1 h at 37 ◦C with albumin
(100 ml of a 1% solution (w/v); Biomol, Hamburg, Germany).
Protein extracts from SW480 colon adenocarcinoma cells were
prepared by sonication of cells suspended in 50 mM Tris/HCl
buffer (pH 8.0) containing 150 mM NaCl and 1% (v/v) Nonidet
P-40. Aliquots of the solution with (glyco)proteins (supernatant
after centrifugation; 0.5 mg/well) were kept in microtiter plate
wells overnight for coating as described above. Incubation with
lectin-containing solution in the absence and presence of tested
compounds was performed for 1 h at 37 ◦C and the extent of lectin
binding was spectrophotometrically determined after colorimetric
detection of biotin with streptavidin-peroxidase conjugate (Sigma)
as described.23 Assays were routinely run in triplicates in up to six
independent series with eight concentrations of sugar, standard
deviations not exceeding 13.7%.
Isothermal titration calorimetry
The calorimetric titrations were performed at 25 ◦C with a Micro-
cal MCS-ITC microcalorimeter (Microcal LLC., Northampton,
MA, USA). VAA samples were exhaustively dialyzed against
5 mM sodium phosphate buffer, pH 7.2, containing 0.2 M NaCl
(PBS), whereas PBS containing 4 mM b-mercaptoethanol was
used for equilibration in the case of human galectin-4. For
calorimetric titrations of galectin-4 with DTDG, the reducing
agent was excluded from the last dialysis buffer in order to
avoid reduction of the glycosyldisulfide. Sugar solutions were
prepared using the last dialysis buffer. Titrations were performed
by stepwise injections of ligand-containing solution into the
reaction cell loaded with the protein solution at concentrations of
117–337.5 mM, depending on the lectin. VAA concentrations were
routinely determined using a colorimetric assay ascertained to be
applicable for AB toxins, theoretical molar adsorption coefficients
were used for galectin-4.24 The heat developed by ligand dilution
was determined separately and subtracted from the total heat
produced following each injection. Titration data were analyzed
using the Microcal-ITC Origin software. The concentration of
the momomer of galectin-4 and of the covalently linked AB
heterodimer of VAA was used as input in the fitting procedures.
STD NMR experiments
All experiments were performed at a lectin concentration of 50 mM
on a Bruker Avance DRX 500MHzNMR spectrometer equipped
with a 5 mm TXI inverse probe head achieving protein saturation
by 40 selective 70 dB Gaussian pulses of 50 ms duration and
a total number of 360 (VAA) or 720 (galectins) scans.8,25 The
ligand to protein ratio was set to 80 : 1, competition experiments
between lactose and the derivatives were performed up to reaching
equimolar concentrations. All details on epitope mapping and
competition can be obtained upon request from the authors.
Quantum mechanical methods, partial charges, and molecular
mechanics force field
Starting from the geometry of the crystallographic structure of lac-
tose in the PDB file 1GZW,26 and of TDG in the PDB file 1A78,12a
we constructed structures for TDG and DTDG, which were
subjected to a full geometry optimization by quantum mechanical
calculations based on the Gaussian03 program27 using the B3LYP
method and a 6-31G(d) basis set. The resulting wavefunctions
were used to calculate electrostatic potential-derived (ESP) charges
employing the RESP methodology,28 as implemented in the
Amber 9 suite of programs (http://amber.scripps.edu/). For
the calculation of dihedral parameters for the torsional barriers
around the bonds involving the S atom in TDG and DTDG we
used the methyl derivatives Gal-S-Me and Gal-S-S-Me. These
values were calculated so as to reproduce, in the AMBER force
field, the energy values calculated ab initio inGaussian03 (keyword
SCAN) upon rotation of the bond in 20◦ steps. The remaining
bonded and nonbonded parameters were assigned, by analogy or
through interpolation from those already present in the AMBER
database, in a way consistent with the Glycam-04 force field
for carbohydrates (http://glycam.ccrc.uga.edu), which has been
tested widely and used successfully in simulations of the type
described herein.
Docking analysis
Docking of TDG and DTDG into the binding sites of VAA6i and
human galectin-126 was based on AutoDock 4.2 application.29 We
first validatedAutoDockby testing its ability to predict the lactose-
binding mode seen in the crystal structure of human galectin-1
(1GZW). Crystallographic water molecules that were identified as
important for binding were kept within the docking calculations.
From a preceding conformational analysis, different conformers
were selected as starting geometries to be docked. Evaluation of
the finally docked structures indicated that AutoDock was able to
predict the bound-state conformer. The same protocol was applied
to TDG and DTDG: the Lamarckian genetic algorithm (LGA)
implemented in AutoDock was used, by randomly changing the
torsion angles and overall orientation of the molecule (100 runs
with 2 500 000 evaluations and a population size of 150 were
selected). The mutation and crossover rates were set to 0.80
and 0.02, respectively, and the maximal number of generations
was 27 000; elitism was set to 1 and the local search frequency
to 0.06. Search parameters were chosen from those previously
5452 | Org. Biomol. Chem., 2011, 9, 5445–5455 This journal is © The Royal Society of Chemistry 2011
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established for docking of carbohydrates, and the grid box was
restricted around galectin-1’s contact site for lactose. From careful
analysis of the docking results, the binding pose with the lowest
docking energy was selected as the starting point for performing
MD simulations in explicit water. All details on calculations are
available upon request.
Molecular dynamics simulations
For each of the two free ligands 6-ns MD simulations were carried
out employing the calculated parameters, using Amber 9. Each
ligand was placed in a 8 A˚-deep truncated octahedral box of
explicit TIP3P water molecules. The equilibration phase started
with energy minimisation of the solvent, followed by an energy
minimisation of the entire system without restraints. The system
was then heated up from 10 K to 298 K during 100 ps with weak
restraints on the solute (positional restraints to a-carbon atoms),
followed by a 100 ps MD simulation at constant temperature and
pressure (1 atm), without restrictions. Equilibrated structures were
used as starting points for 6-ns production trajectories, performed
at constant pressure (1 atm) and temperature (288 K), as in the
NMR experiments, controlled by the Langevin thermostat with a
collision frequency of 1.0 ps-1. During the simulations, SHAKE
algorithm was turned on and applied to all hydrogen atoms. A
cut-off of 10 A˚ for all nonbonded interactions was adopted. An in-
tegration time step of 2 fs was employed, and periodic boundaries
conditions were applied throughout. During all simulations, the
Particle Mesh Ewald (PME) method30 was used to compute long-
range electrostatic interactions. Minimisation, equilibration and
production phases were carried out by using the sander module,
while analyses of the simulations were performed with ptraj mod-
ule (http://amber.scripps.edu/). The visualization of trajectories
was performed using VMD software (http://www.ks.uiuc.edu/).
Data were processed and plotted using R software (http://www.r-
project.org/). Concerning the conformational behavior of the
ligands during the 6-ns MD simulations, exo-anomeric regions
were sampled for both thioglycosidic torsions, while w angle
around the C5–C6 bond took the expected gg and gt orientations.
The set of charges and parameters described before was employed
for the MD simulations of complexes with galectin-1. Starting
geometries were selected from docking studies as the poses with
the lowest docking energy, in full agreement with the NMR data.
6-ns MD simulations of the sugar/receptor complex were carried
out following a protocol identical to that described above for the
free ligands.
Inhibition cell assay
Cells of the B-lymphoblastic line Croco II, the colon adenocarci-
noma line SW480 and the pancreatic adenocarcinoma line Capan-
1 reconstituted for tumor suppressor p16INK4a status were cultured
and processed for cell staining in a two-step procedure using a
streptavidin/R-phycoerythrin conjugate (Sigma), as described in
detail in our previous study on dynamic combinatorial thiogly-
coside libraries to maintain identical conditions.4d Decrease of
fluorescent staining (as percentage of positive cells and intensity)
served as indicator of the inhibitory capacity of the tested
compounds. Up to five series of independent measurements on
aliquots of cell suspensions of the same passage were run in
triplicates, with standard deviation not exceeding 15.5%.
Inhibition radioassays
The two separate carbohydrate recognition domains of human
galectin-4 were radioiodinated using IODO-GEN (Pierce Euro-
chemie), as described previously.13 Specific activities of 0.57 and
0.35 mCi/mg were obtained for the N- and C-terminal domains,
respectively. These 125I-labelled proteins were first tested for
maintained binding capacity and then for optimal test conditions.
For the N-domain, the amount of labelled protein bound to
agarose beads presenting lactose (Sigma) was measured. Aliquots
of 10 ml of sedimented resin were incubated with the 125I-protein-
containing solution (15000 cpm) in the absence or presence
of different concentrations of test compound (final volume:
50 ml). The buffer used was PBS containing 0.1% Tween-20 and
0.4 mM b-mercaptoethanol. The inhibitory capacity of DTDG
was evaluated in parallel experiments carried out in the absence of
b-mercaptoethanol. After 2 h at 20 ◦C with regular shaking, the
samples were centrifuged and the radioactivity of the supernatant
counted. The C-terminal domain was assayed using 100 mg-
asialofibrin films on the surface of plastic microwells essentially
as described,13 except that the plate surface was treated with a
2.5% solution of Tween-20 for 1 h at 37 ◦C to preclude adsorption
of protein and the buffer used was PBS containing 0.1% Tween-
20 and 0.4 mM b-mercaptoethanol. Again, the reducing agent
was omitted when evaluating the ligand properties of DTDG.
For the two systems, i.e. lactose-agarose and asialofibrin films,
carbohydrate-independent bindingwas determined in the presence
of 0.1 M lactose and subtracted from all measurements.
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